PRT811 is an oral PRMT5 inhibitor designed to have high potency and selectivity and optimized brain exposure. It is in Phase 1 clinical development for patients with PRMT5-dependent cancers, including uveal melanoma and IDH1 mutated high grade gliomas.
Differentiated PRMT5 Inhibitor
- Highly selective, potent, oral
- High, sustained brain penetration in preclinical studies
Applicability in Both Solid Tumors and Heme
- Strong scientific rationale and robust preclinical activity across broad range of cancers
- Early clinical signals in biomarker selected patients
Optimized PK Profile
- High oral bioavailability and optimal half-life (4-6 hrs) to maximize therapeutic window
- Potential best-in-class safety profile
Potential Rapid Path to Market
- Potential for accelerated approval pathway
- Opportunity in multiple cancer types